<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="evaluation" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1002" relname="span">Bone disorders , especially osteoporosis , are becoming increasingly prevalent</segment>
<segment id="3" parent="1003" relname="joint">as the aging population grows ,</segment>
<segment id="4" parent="1003" relname="joint">and bone fractures also occur frequently .</segment>
<segment id="5" parent="1004" relname="joint">Osteoporosis contributes significantly to global healthcare costs ,</segment>
<segment id="6" parent="1004" relname="joint">and the treatment of osteoporosis remains a great challenge .</segment>
<segment id="7" parent="1007" relname="span">Thus , new bone anabolic drugs need to be developed for the prevention and treatment of osteoporosis .</segment>
<segment id="8" parent="1010" relname="span">Bone morphogenetic protein 2</segment>
<segment id="9" parent="8" relname="restatement">( BMP2 )</segment>
<segment id="10" parent="1011" relname="span">is one of the most important growth factors</segment>
<segment id="11" parent="10" relname="elaboration">that induce osteoblast differentiation</segment>
<segment id="12" parent="1008" relname="joint">and stimulate bone or cartilage formation .</segment>
<segment id="13" parent="1013" relname="span">BMP2 has been widely used in the clinic</segment>
<segment id="14" parent="13" relname="purpose">to promote bone formation .</segment>
<segment id="15" parent="1004" relname="joint">However , the therapeutic dose of BMP2 is very expensive ,</segment>
<segment id="16" parent="1016" relname="span">and there are some life-threatening side effects</segment>
<segment id="17" parent="16" relname="elaboration">that can occur with larger doses .</segment>
<segment id="18" parent="1018" relname="span">Hence , it is necessary to find additional agents or methods for the improvement of BMP2 itself</segment>
<segment id="19" parent="18" relname="purpose">to intensify the osteogenic effects of BMP2 .</segment>
<segment id="20" parent="1019" relname="joint">The combination of BMP2 and these small molecules can promote BMP2-mediated osteoblast differentiation</segment>
<segment id="21" parent="1020" relname="sequence">and reduces the risk of its side effects in the treatment of bone diseases .</segment>
<segment id="22" parent="1022" relname="span">From a clinical perspective , these small molecules</segment>
<segment id="23" parent="22" relname="elaboration">that regulate BMP2 activity provide powerful tools for the treatment of osteoporosis and fracture repair .</segment>
<segment id="24" parent="1025" relname="span">Icariin</segment>
<segment id="25" parent="24" relname="restatement">( ICA )</segment>
<segment id="26" parent="1024" relname="same_unit">( the chemical structure is shown in</segment>
<segment id="27" parent="1027" relname="preparation">Figure 1</segment>
<segment id="28" parent="1028" relname="span">) is the main active flavonoid glucoside from herbs of the genus Epimedium ;</segment>
<segment id="29" parent="1029" relname="joint">these herbs are used in traditional Chinese medicine</segment>
<segment id="30" parent="1029" relname="joint">and have long been prescribed for the treatment of bone fractures and osteoporosis as a bone-protecting agent .</segment>
<segment id="31" parent="1031" relname="joint">In addition to promoting bone regeneration and repair ,</segment>
<segment id="32" parent="1033" relname="span">ICA also has many beneficial pharmacological and biological activities ,</segment>
<segment id="33" parent="32" relname="elaboration">including neuroprotective effects ; protective effects against atherosclerosis ;</segment>
<segment id="34" parent="1033" relname="elaboration">antitumor effects ; anti-inflammatory and antioxidant effects ; and improved sexual function effects .</segment>
<segment id="35" parent="1036" relname="attribution">Several animal and cell studies have shown</segment>
<segment id="36" parent="1036" relname="joint">that treatment with ICA can increase osteogenic differentiation</segment>
<segment id="37" parent="1036" relname="joint">and reduce bone loss in vivo and in vitro .</segment>
<segment id="38" parent="1037" relname="joint">The extremely low cost of ICA and its strong bone regenerative effects indicate its potential in clinical applications .</segment>
<segment id="39" parent="1039" relname="span">The cAMP/PKA/CREB axis is a vital pathway</segment>
<segment id="40" parent="39" relname="elaboration">that regulates osteogenic differentiation and mineralization .</segment>
<segment id="41" parent="1042" relname="attribution">Several previous studies have reported</segment>
<segment id="42" parent="1042" relname="span">that PTH affects osteoblastic cells</segment>
<segment id="43" parent="42" relname="means">by activating the cAMP/PKA/CREB axis .</segment>
<segment id="44" parent="1045" relname="attribution">Several studies have reported</segment>
<segment id="45" parent="1046" relname="span">that pretreatment of human mesenchymal stem cells</segment>
<segment id="46" parent="45" relname="restatement">( MSCs )</segment>
<segment id="47" parent="1045" relname="same_unit">with cAMP analogs , adenylate cyclase activators or phosphodiesterase inhibitors can enhance bone formation .</segment>
<segment id="48" parent="1048" relname="span">In the present study , we combined ICA and BMP2</segment>
<segment id="49" parent="48" relname="purpose">to promote osteogenesis for the first time .</segment>
<segment id="50" parent="51" relname="attribution">We aimed to determine</segment>
<segment id="51" parent="1050" relname="span">whether ICA could enhance the osteogenic induction of BMP2 in C2C12 cells .</segment>
<segment id="52" parent="53" relname="attribution">We concluded</segment>
<segment id="53" parent="1052" relname="span">that the combination of ICA and BMP2 could promote BMP2-mediated osteoblast differentiation in a dose-dependent manner .</segment>
<segment id="54" parent="1055" relname="attribution">We also found</segment>
<segment id="55" parent="1055" relname="span">that ICA stimulates BMP2-mediated osteogenesis</segment>
<segment id="56" parent="55" relname="means">by activating the cAMP/PKA/CREB signaling pathway .</segment>
<segment id="57" parent="1057" relname="span">Therefore , ICA is a promising candidate as an alternative for BMP2 or as a promoter</segment>
<segment id="58" parent="57" relname="purpose">for enhancing the therapeutic effects of BMP2 .</segment>
<segment id="59" parent="1057" relname="evaluation">This combination will reduce the risk of side effects from BMP2 in the treatment of bone diseases such as osteoporosis .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1004" relname="preparation"/>
<group id="1003" type="multinuc" parent="2" relname="circumstance"/>
<group id="1004" type="multinuc" parent="1001" relname="span"/>
<group id="1007" type="span" parent="1004" relname="joint"/>
<group id="1008" type="multinuc" parent="7" relname="elaboration"/>
<group id="1009" type="multinuc" parent="1008" relname="joint"/>
<group id="1010" type="span" parent="1009" relname="same_unit"/>
<group id="1011" type="span" parent="1009" relname="same_unit"/>
<group id="1013" type="span" parent="1004" relname="joint"/>
<group id="1015" type="span" parent="1004" relname="joint"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1017" type="multinuc" parent="1016" relname="elaboration"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="multinuc" parent="1017" relname="joint"/>
<group id="1020" type="multinuc" parent="1019" relname="joint"/>
<group id="1021" type="multinuc" parent="1020" relname="sequence"/>
<group id="1022" type="span" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1021" relname="joint"/>
<group id="1024" type="multinuc" parent="1026" relname="preparation"/>
<group id="1025" type="span" parent="1024" relname="same_unit"/>
<group id="1026" type="span" parent="1023" relname="span"/>
<group id="1027" type="multinuc" parent="1026" relname="span"/>
<group id="1028" type="span" parent="1027" relname="joint"/>
<group id="1029" type="multinuc" parent="28" relname="elaboration"/>
<group id="1030" type="multinuc" parent="1027" relname="joint"/>
<group id="1031" type="multinuc" parent="1030" relname="joint"/>
<group id="1032" type="span" parent="1031" relname="joint"/>
<group id="1033" type="span" parent="1032" relname="span"/>
<group id="1034" type="multinuc" parent="1030" relname="joint"/>
<group id="1035" type="span" parent="1034" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="span"/>
<group id="1037" type="multinuc" parent="1034" relname="joint"/>
<group id="1038" type="multinuc" parent="1037" relname="joint"/>
<group id="1039" type="span" parent="1038" relname="joint"/>
<group id="1040" type="multinuc" parent="1038" relname="joint"/>
<group id="1041" type="span" parent="1040" relname="joint"/>
<group id="1042" type="span" parent="1041" relname="span"/>
<group id="1043" type="multinuc" parent="1040" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="multinuc" parent="1044" relname="span"/>
<group id="1046" type="span" parent="1045" relname="same_unit"/>
<group id="1047" type="multinuc" parent="1043" relname="joint"/>
<group id="1048" type="span" parent="1047" relname="joint"/>
<group id="1049" type="multinuc" parent="1047" relname="joint"/>
<group id="1050" type="span" parent="1049" relname="joint"/>
<group id="1051" type="span" parent="1049" relname="joint"/>
<group id="1052" type="span" parent="1051" relname="span"/>
<group id="1053" type="multinuc" parent="1052" relname="elaboration"/>
<group id="1054" type="span" parent="1053" relname="joint"/>
<group id="1055" type="span" parent="1054" relname="span"/>
<group id="1056" type="span" parent="1053" relname="joint"/>
<group id="1057" type="span" parent="1056" relname="span"/>
	</body>
</rst>
